DrugPatentWatch Database Preview
RASUVO Drug Profile
Email this page to a colleague
» See Plans and PricingWhich patents cover Rasuvo, and when can generic versions of Rasuvo launch?
Rasuvo is a drug marketed by Medexus and is included in one NDA. There is one patent protecting this drug.
This drug has twenty-nine patent family members in twenty-one countries.
The generic ingredient in RASUVO is methotrexate. There are twenty drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the methotrexate profile page.
US ANDA Litigation and Generic Entry Outlook for Rasuvo
Indicators of Generic Entry
Summary for RASUVO
| International Patents: | 29 |
| US Patents: | 1 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: | 1 |
| Bulk Api Vendors: | 120 |
| Clinical Trials: | 2 |
| Patent Applications: | 6,503 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for RASUVO |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for RASUVO |
| DailyMed Link: | RASUVO at DailyMed |
Recent Clinical Trials for RASUVO
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| University of Wisconsin, Madison | Phase 1 |
| University of Virginia | Phase 1 |
| Vanderbilt University | Phase 1 |
Pharmacology for RASUVO
| Drug Class | Folate Analog Metabolic Inhibitor |
| Mechanism of Action | Folic Acid Metabolism Inhibitors |
US Patents and Regulatory Information for RASUVO
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Medexus | RASUVO | methotrexate | SOLUTION;SUBCUTANEOUS | 205776-001 | Jul 10, 2014 | RX | Yes | Yes | Start Trial | Start Trial | Start Trial | ||||
| Medexus | RASUVO | methotrexate | SOLUTION;SUBCUTANEOUS | 205776-007 | Jul 10, 2014 | RX | Yes | Yes | Start Trial | Start Trial | Start Trial | ||||
| Medexus | RASUVO | methotrexate | SOLUTION;SUBCUTANEOUS | 205776-004 | Jul 10, 2014 | RX | Yes | Yes | Start Trial | Start Trial | Start Trial | ||||
| Medexus | RASUVO | methotrexate | SOLUTION;SUBCUTANEOUS | 205776-008 | Jul 10, 2014 | RX | Yes | Yes | Start Trial | Start Trial | Start Trial | ||||
| Medexus | RASUVO | methotrexate | SOLUTION;SUBCUTANEOUS | 205776-002 | Jul 10, 2014 | RX | Yes | Yes | Start Trial | Start Trial | Start Trial | ||||
| Medexus | RASUVO | methotrexate | SOLUTION;SUBCUTANEOUS | 205776-003 | Jul 10, 2014 | RX | Yes | Yes | Start Trial | Start Trial | Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for RASUVO
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Denmark | 2046332 | Start Trial |
| World Intellectual Property Organization (WIPO) | 2008009476 | Start Trial |
| Montenegro | 01940 | Start Trial |
| Portugal | 2046332 | Start Trial |
| Germany | 502007005972 | Start Trial |
| European Patent Office | 2292235 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
